{"nctId":"NCT01347762","briefTitle":"Nabilone for Cannabis Dependence: A Pilot Study","startDateStruct":{"date":"2010-06"},"conditions":["Cannabis Dependence","Marijuana Dependence"],"count":84,"armGroups":[{"label":"Nabilone","type":"EXPERIMENTAL","interventionNames":["Drug: Nabilone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Nabilone","otherNames":["Nabilone (Cesamet), CSA Drug Code 7379, Schedule II, NDC 0037-1221-50"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age range 18-45 years\n* DSM-IV diagnosis of cannabis dependence, based on the Structured Clinical Interview for DSM-IV (SCID)\n* express a desire to quit cannabis use within the next 30 days\n* have used cannabis on more than4 days within the past 30 days\n* for women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy and monthly pregnancy tests\n* consent for us to communicate with their prescribing clinician\n* furnish the names of 2 locators, who would assist study staff in locating them during the study period\n* live close enough to McLean Hospital to attend study visits\n* plan to stay in the Boston area for the next 3 months\n* are willing and able to sign informed consent.\n\nExclusion Criteria:\n\n* current diagnosis of other drug or alcohol dependence (excluding nicotine)\n* recent (within 3 months) significant cardiac disease\n* current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder\n* current medical condition (including significant laboratory abnormalities, such as liver function tests \\>5 times the upper limit of normal range) that could prevent regular study attendance\n* mental retardation or organic mental disorder\n* acutely dangerous or suicidal behavior\n* currently in a residential treatment setting in which substance use is monitored and restricted, since the restricted access to drugs could represent an important confounding variable\n* pregnant, nursing, or, if a woman of childbearing potential, not using a form of birth control judged by the investigator to be effective\n* concomitant daily treatment with opioid analgesics, sedative hypnotics, or other known CNS depressants\n* known hypersensitivity to cannabinoids or sesame oil\n* disease of the gastrointestinal system, liver, or kidneys that may impede metabolism or excretion of nabilone\n* inability to read or write in English. The potential hazards of a Schedule II medication like nabilone underscore the importance of English proficiency in this medication trial.\n* unwilling or unable to participate in MRI scanning (e.g., those having pacemakers, bone plates, screws, etc.; claustrophobia)\n* a history of seizures, head trauma or other history of CNS insult that could predispose the subject to seizures .","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Cannabis Use at 10 Weeks","description":"Quantitative cannabis urine screens (THC-COOH:Creatinine ratio)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"268.8","spread":"183.0"},{"groupId":"OG001","value":"286.7","spread":"349.7"},{"groupId":"OG002","value":"490.3","spread":"615.0"},{"groupId":"OG003","value":"216.9","spread":"188.5"}]}]}]},{"type":"PRIMARY","title":"Number of Marijuana Inhales Per Day","description":"Average # of marijuana inhales per day during baseline compared to after 10 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"31.0"},{"groupId":"OG001","value":"22.6","spread":"30.6"},{"groupId":"OG002","value":"15.8","spread":"35.6"},{"groupId":"OG003","value":"10.6","spread":"14.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Neuropsychological Performance at 4 Weeks","description":"performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner","classes":[]},{"type":"SECONDARY","title":"Change From Baseline Cannabis Use at 14 Weeks","description":"quantitative urine screens - Comparing the THC-COOH to creatinine ratio at baseline and at the end of the study (Week 14)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"524.2","spread":"466.2"},{"groupId":"OG001","value":"326.7","spread":"403.7"},{"groupId":"OG002","value":"297.7","spread":"291.8"},{"groupId":"OG003","value":"222","spread":"186.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neuropsychological Performance at 10 Weeks","description":"performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}